Effect of rimonabant on energy intake, motivation to eat and body weight with or without hypocaloric diet: the REBA study

J E Blundell, S Jebb, R J Stubbs, J R Wilding, C L Lawton, L Browning, S Whybrow, J C G Halford

Research output: Contribution to journalAbstract

Abstract

Background: In clinical trials to date, rimonabant, the first selectiveCB1receptor blocker improved multiple cardiometabolic risk factors. The Rimonabant Eating Behaviour Assessment (REBA) study examined the effect of rimonabant over 12 weeks on energy intake under controlled and free-living conditions. Methods: After 2-week’s run in, 156 obese patients (mean body mass index 36.5 kg/m2) were randomized to rimonabant 20 mg/day or placebo with/without a 600 kcal hypocaloric diet. Energy intake was assessed at Weeks 3/4 and 10/11 during controlled high- and low-fat meals, and by food diaries under free-living conditions. Motivation to eat and food behaviour were assessed by visual analogue scales, food preference forced choice tests, and End of Day Questionnaires. Results: Rimonabant 20 mg/day significantly reduced energy intake by 17% and 15.6% from baseline during high- and low-fat meals, respectively, at Weeks 3/4 (P = 0.011 and < 0.001 vs. placebo). Corresponding reductions at Weeks 10/11 were 23% and 16.7%(P = 0.002 and < 0.001 vs. placebo). Mean weight loss at last follow-up was greater with rimonabant 20 mg/day than placebo(-4.0 vs. -1.1 kg; P < 0.001). Effects on food intake were independent of food type and pleasantness. Rimonabant reduced pre-meal motivation to eat with no change in sensation of fullness or contentedness. There was no effect on macronutrient selection, food preferences, or hedonic evaluation of foods eaten during free-living assessments.Conclusions: Rimonabant 20 mg/day reduced total energy intake by overweight/obese patients during high- and low-fat meals, independent of normal or hypocaloric diet prescription.
Original languageEnglish
Pages (from-to)104
Number of pages1
JournalObesity Reviews
Volume7
Issue numberSupplement 2
Early online date15 Aug 2006
Publication statusPublished - Sep 2006

Fingerprint

rimonabant
Feeding Behavior
Energy Intake
Motivation
Body Weight
Diet
Fats
Meals
Placebos
Food Preferences
Social Conditions
Food
Diet Records
Pleasure
Visual Analog Scale

Cite this

Blundell, J. E., Jebb, S., Stubbs, R. J., Wilding, J. R., Lawton, C. L., Browning, L., ... Halford, J. C. G. (2006). Effect of rimonabant on energy intake, motivation to eat and body weight with or without hypocaloric diet: the REBA study. Obesity Reviews, 7(Supplement 2), 104.

Effect of rimonabant on energy intake, motivation to eat and body weight with or without hypocaloric diet : the REBA study. / Blundell, J E; Jebb, S; Stubbs, R J; Wilding, J R; Lawton, C L; Browning, L; Whybrow, S; Halford, J C G.

In: Obesity Reviews, Vol. 7, No. Supplement 2, 09.2006, p. 104.

Research output: Contribution to journalAbstract

Blundell, JE, Jebb, S, Stubbs, RJ, Wilding, JR, Lawton, CL, Browning, L, Whybrow, S & Halford, JCG 2006, 'Effect of rimonabant on energy intake, motivation to eat and body weight with or without hypocaloric diet: the REBA study', Obesity Reviews, vol. 7, no. Supplement 2, pp. 104.
Blundell JE, Jebb S, Stubbs RJ, Wilding JR, Lawton CL, Browning L et al. Effect of rimonabant on energy intake, motivation to eat and body weight with or without hypocaloric diet: the REBA study. Obesity Reviews. 2006 Sep;7(Supplement 2):104.
Blundell, J E ; Jebb, S ; Stubbs, R J ; Wilding, J R ; Lawton, C L ; Browning, L ; Whybrow, S ; Halford, J C G. / Effect of rimonabant on energy intake, motivation to eat and body weight with or without hypocaloric diet : the REBA study. In: Obesity Reviews. 2006 ; Vol. 7, No. Supplement 2. pp. 104.
@article{62a04ea4788f4a95928c3205e1e061cc,
title = "Effect of rimonabant on energy intake, motivation to eat and body weight with or without hypocaloric diet: the REBA study",
abstract = "Background: In clinical trials to date, rimonabant, the first selectiveCB1receptor blocker improved multiple cardiometabolic risk factors. The Rimonabant Eating Behaviour Assessment (REBA) study examined the effect of rimonabant over 12 weeks on energy intake under controlled and free-living conditions. Methods: After 2-week’s run in, 156 obese patients (mean body mass index 36.5 kg/m2) were randomized to rimonabant 20 mg/day or placebo with/without a 600 kcal hypocaloric diet. Energy intake was assessed at Weeks 3/4 and 10/11 during controlled high- and low-fat meals, and by food diaries under free-living conditions. Motivation to eat and food behaviour were assessed by visual analogue scales, food preference forced choice tests, and End of Day Questionnaires. Results: Rimonabant 20 mg/day significantly reduced energy intake by 17{\%} and 15.6{\%} from baseline during high- and low-fat meals, respectively, at Weeks 3/4 (P = 0.011 and < 0.001 vs. placebo). Corresponding reductions at Weeks 10/11 were 23{\%} and 16.7{\%}(P = 0.002 and < 0.001 vs. placebo). Mean weight loss at last follow-up was greater with rimonabant 20 mg/day than placebo(-4.0 vs. -1.1 kg; P < 0.001). Effects on food intake were independent of food type and pleasantness. Rimonabant reduced pre-meal motivation to eat with no change in sensation of fullness or contentedness. There was no effect on macronutrient selection, food preferences, or hedonic evaluation of foods eaten during free-living assessments.Conclusions: Rimonabant 20 mg/day reduced total energy intake by overweight/obese patients during high- and low-fat meals, independent of normal or hypocaloric diet prescription.",
author = "Blundell, {J E} and S Jebb and Stubbs, {R J} and Wilding, {J R} and Lawton, {C L} and L Browning and S Whybrow and Halford, {J C G}",
note = "1777; Submitted to the International Congress on Obesity (ICO), 3-8 September, Sydney, Australia GOT PDF",
year = "2006",
month = "9",
language = "English",
volume = "7",
pages = "104",
journal = "Obesity Reviews",
issn = "1467-7881",
publisher = "Wiley-Blackwell",
number = "Supplement 2",

}

TY - JOUR

T1 - Effect of rimonabant on energy intake, motivation to eat and body weight with or without hypocaloric diet

T2 - the REBA study

AU - Blundell, J E

AU - Jebb, S

AU - Stubbs, R J

AU - Wilding, J R

AU - Lawton, C L

AU - Browning, L

AU - Whybrow, S

AU - Halford, J C G

N1 - 1777; Submitted to the International Congress on Obesity (ICO), 3-8 September, Sydney, Australia GOT PDF

PY - 2006/9

Y1 - 2006/9

N2 - Background: In clinical trials to date, rimonabant, the first selectiveCB1receptor blocker improved multiple cardiometabolic risk factors. The Rimonabant Eating Behaviour Assessment (REBA) study examined the effect of rimonabant over 12 weeks on energy intake under controlled and free-living conditions. Methods: After 2-week’s run in, 156 obese patients (mean body mass index 36.5 kg/m2) were randomized to rimonabant 20 mg/day or placebo with/without a 600 kcal hypocaloric diet. Energy intake was assessed at Weeks 3/4 and 10/11 during controlled high- and low-fat meals, and by food diaries under free-living conditions. Motivation to eat and food behaviour were assessed by visual analogue scales, food preference forced choice tests, and End of Day Questionnaires. Results: Rimonabant 20 mg/day significantly reduced energy intake by 17% and 15.6% from baseline during high- and low-fat meals, respectively, at Weeks 3/4 (P = 0.011 and < 0.001 vs. placebo). Corresponding reductions at Weeks 10/11 were 23% and 16.7%(P = 0.002 and < 0.001 vs. placebo). Mean weight loss at last follow-up was greater with rimonabant 20 mg/day than placebo(-4.0 vs. -1.1 kg; P < 0.001). Effects on food intake were independent of food type and pleasantness. Rimonabant reduced pre-meal motivation to eat with no change in sensation of fullness or contentedness. There was no effect on macronutrient selection, food preferences, or hedonic evaluation of foods eaten during free-living assessments.Conclusions: Rimonabant 20 mg/day reduced total energy intake by overweight/obese patients during high- and low-fat meals, independent of normal or hypocaloric diet prescription.

AB - Background: In clinical trials to date, rimonabant, the first selectiveCB1receptor blocker improved multiple cardiometabolic risk factors. The Rimonabant Eating Behaviour Assessment (REBA) study examined the effect of rimonabant over 12 weeks on energy intake under controlled and free-living conditions. Methods: After 2-week’s run in, 156 obese patients (mean body mass index 36.5 kg/m2) were randomized to rimonabant 20 mg/day or placebo with/without a 600 kcal hypocaloric diet. Energy intake was assessed at Weeks 3/4 and 10/11 during controlled high- and low-fat meals, and by food diaries under free-living conditions. Motivation to eat and food behaviour were assessed by visual analogue scales, food preference forced choice tests, and End of Day Questionnaires. Results: Rimonabant 20 mg/day significantly reduced energy intake by 17% and 15.6% from baseline during high- and low-fat meals, respectively, at Weeks 3/4 (P = 0.011 and < 0.001 vs. placebo). Corresponding reductions at Weeks 10/11 were 23% and 16.7%(P = 0.002 and < 0.001 vs. placebo). Mean weight loss at last follow-up was greater with rimonabant 20 mg/day than placebo(-4.0 vs. -1.1 kg; P < 0.001). Effects on food intake were independent of food type and pleasantness. Rimonabant reduced pre-meal motivation to eat with no change in sensation of fullness or contentedness. There was no effect on macronutrient selection, food preferences, or hedonic evaluation of foods eaten during free-living assessments.Conclusions: Rimonabant 20 mg/day reduced total energy intake by overweight/obese patients during high- and low-fat meals, independent of normal or hypocaloric diet prescription.

M3 - Abstract

VL - 7

SP - 104

JO - Obesity Reviews

JF - Obesity Reviews

SN - 1467-7881

IS - Supplement 2

ER -